ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
TriSalus Life Sciences Inc

TriSalus Life Sciences Inc (TLSI)

4.50
0.04
(0.90%)
Closed 14 November 8:00AM
4.49
-0.01
(-0.22%)
After Hours: 11:59AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
4.50
Bid
1.78
Offer
5.00
Volume
15,070
4.29 Day's Range 4.50
3.32 52 Week Range 10.42
Previous Close
4.46
Open
4.48
Last Trade
348
@
4.5
Last Trade Time
Average Volume (3m)
43,594
Financial Volume
US$ 66,862
VWAP
4.4368

TLSI Latest News

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced...

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and...

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and...

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced...

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced...

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective...

TriSalus Reports Q2 2024 Financial Results and Business Update

Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2...

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to...

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6918.11023622053.814.653.81264134.39150517CS
40.071.580135440184.434.653.775839213394.16628425CS
12-0.93-17.12707182325.435.783.775839435944.73008027CS
26-5.32-54.17515274959.8210.243.775839393965.55911069CS
520.337.913669064754.1710.423.32482227.04807759CS
156-9.3-67.391304347813.816.243.32476246.85833532CS
260-9.3-67.391304347813.816.243.32476246.85833532CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MVSTMicrovast Holdings Inc
US$ 0.7951
(340.01%)
1.08B
QUBTQuantum Computing Inc
US$ 2.66
(92.75%)
102.15M
PULMPulmatrix Inc
US$ 3.56
(73.66%)
3.63M
BTCTBTC Digital Ltd
US$ 17.65
(68.10%)
45.02M
NMHINatures Miracle Holding Inc
US$ 0.142
(65.69%)
1.33B
SYRSSyros Pharmaceuticals Inc
US$ 0.359
(-86.85%)
38.53M
GCTKGlucoTrack Inc
US$ 0.36
(-77.06%)
6.58M
PETWag Group Company
US$ 0.21
(-67.98%)
14.68M
GLXGGalaxy Payroll Group Ltd
US$ 6.24
(-56.39%)
2.96M
XFORX4 Pharmaceuticals Inc
US$ 0.2773
(-53.17%)
18.56M
NMHINatures Miracle Holding Inc
US$ 0.142
(65.69%)
1.33B
MVSTMicrovast Holdings Inc
US$ 0.7951
(340.01%)
1.09B
ELABElevai Labs Inc
US$ 0.0247
(31.38%)
541.65M
AGRIAgriFORCE Growing Systems Ltd
US$ 0.0486
(2.53%)
291.82M
NVDANVIDIA Corporation
US$ 146.27
(-1.36%)
191.62M